Dr. Lal PathLabs (DLPL), one of India’s largest diagnostic networks, has introduced the country’s first dedicated Complement Testing Lab. With this launch, the organisation strengthens its leadership in autoimmune diagnostics and brings globally benchmarked complement assays to Indian patients—many of them available domestically for the very first time. This advancement promises faster, more accurate, and earlier diagnosis of autoimmune, kidney-related, and recurrent infection disorders.
Why Complement Testing Is Increasingly Critical
Autoimmune and inflammatory diseases are being recognized more frequently across India. Many patients present with non-specific symptoms such as fever, joint pain, fatigue, swelling, or kidney dysfunction. As a result, they often visit multiple specialists before receiving a definitive diagnosis.
These delays occur because such diseases can progress silently, damaging vital organs long before symptoms become evident. Complement testing offers a critical tool to uncover hidden immune disturbances. By identifying the root cause of vague symptoms, the tests enable earlier diagnosis and timely treatment.
Understanding the Complement System
The complement system comprises a complex network of blood proteins responsible for fighting infections, clearing damaged cells, and protecting essential organs. When this system functions poorly, individuals—especially children—may experience frequent or severe infections. Conversely, when it becomes overactive, it may attack healthy tissues, contributing to conditions such as lupus, vasculitis, rheumatoid arthritis, C3 glomerulopathy, atypical haemolytic uremic syndrome (HUS), transplant rejection, and even sepsis.
Since complement dysfunction can manifest in several ways, measuring proteins such as C3, C4, and C5 becomes crucial. These tests help determine whether the immune system is overactive, underactive, or malfunctioning, forming a vital part of early autoimmune disease diagnosis.
Introducing Advanced Complement Assays in India
“Complement testing has long been underrepresented in India’s diagnostic landscape. By introducing functional and antibody-based assays such as C1q, C5, Factor B, Factor H antibody, AH50, and C1 INH functional—many for the first time in the country—we are offering earlier and more precise insights into immune-mediated disorders,” said Dr. Vandana Lal, Executive Director, Dr. Lal PathLabs. “This launch bridges the gap between research and routine clinical care.”
Mr. Shankha Banerjee, CEO of Dr. Lal PathLabs, added, “As a pioneer in specialized diagnostics, we are proud to offer India’s first comprehensive complement testing platform. This development marks a major step toward faster diagnoses, improved treatment decisions, and better outcomes for millions living with autoimmune and kidney diseases.”
Advanced Technology and High-Quality Standards
As per the press release, the new Complement Testing Lab features state-of-the-art immunoturbidimetric and ELISA platforms, operating under CAP and NABL-accredited quality systems. The facility aims to provide patients with clearer insights into autoimmune and inflammatory conditions.
Better Diagnosis, Better Outcomes
With the introduction of this specialized laboratory, patients can expect faster and more reliable results. Early and accurate diagnosis not only improves clinical outcomes but also reduces long-term healthcare costs and enhances overall quality of life. Dr. Lal PathLabs’ latest initiative marks a significant advancement in India’s diagnostic capabilities and brings essential tests closer to millions who need them.